[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4014/jmb.0910.10027

Biotransformation of Valdecoxib by Microbial Cultures

Srisailam, K. (University College of Pharmaceutical Sciences, Kakatiya University)
Veeresham, C. (University College of Pharmaceutical Sciences, Kakatiya University)

Publication Information

Journal of Microbiology and Biotechnology / v.20, no.4, 2010 , pp. 809-816 More about this Journal

Abstract

Microbial biotransformations can be used to predict mammalian drug metabolism. The present investigation deals with microbial biotransformation of valdecoxib using microbial cultures. Thirty-nine bacterial, fungal, and yeast cultures were used to elucidate the biotransformation pathway of valdecoxib. A number of microorganisms metabolized valdecoxib to various levels to yield nine metabolites, which were identified by HPLC-DAD and LC-MS-MS analyses. HPLC analysis of biotransformed products indicated that a majority of the metabolites are more polar than the substrate valdecoxib. Basing on LC-MS-MS analysis, the major metabolite was identified as a hydroxymethyl metabolite of valdecoxib, whereas the remaining metabolites were produced by carboxylation, demethylation, ring hydroxylation, N-acetylation, or a combination of these reactions. The hydroxymethyl and carboxylic acid metabolites were known to be produced in metabolism by mammals. From the results, it can be concluded that microbial cultures, particularly fungi, can be used to predict mammalian drug metabolism.

Keywords

Biotransformation; microbial; valdecoxib; metabolites; HPLC; LC-MS-MS;

Citations & Related Records

Times Cited By Web Of Science : 0 (Related Records In Web of Science)

Reference

1	Mazier, C., M. Jaouen, M. Sari, and D. Buisson. 2004. Microbial oxidation of terfenadine and ebastine into fexofenadine and carebastine. Bioorg. Med. Chem. Lett. 14: 5423-5426. DOI ScienceOn
2	Harris, R. R., L. Black, S. Surapaneni, T. Kolasa, S. Majest, M. T. Namovic, et al. 2004. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J. Pharmacol. Exp. Ther. 311: 904-912. DOI ScienceOn
3	Huang, H., X. Yang, Q. Li, L. Sun, and D. Zhong. 2006. Biotransformation of tolbutamide to 4'-hydroxytolbutamide by the fungus Cunninghamella blakesleana. Appl. Microbiol. Biotechnol. 72: 486-491. DOI ScienceOn
4	Keshetty, S., R. K. Venisetty, V. Molmoori, and V. Ciddi. 2006. Determination of valdecoxib in serum using HPLC-diode array detector and its application in pharmacokinetic study. Pharmazie 61: 245-246.
5	Golbeck, J. H., S. A. Albaugh, and R. Radmer. 1983. Metabolism of biphenyl by Aspergillus toxicarius: Induction of hydroxylating activity and accumulation of water-soluble conjugates. J. Bacteriol. 156: 49-57.
6	Hansen Jr., E. B., R. H. Heflich, W. A. Korfmacher, D. W. Miller, and C. E. Cerniglia. 1988. Microbial transformation of the antihistamine drug triprolidine hydrochloride. J. Pharm. Sci. 77: 259-264. DOI
7	Foster, B. C., D. L. Wilson, and I. J. McGilveray. 1989. Effect of sparteine and quinidine on the metabolism of methoxyphenamine by Cunninghamella bainieri. Xenobiotica 19: 445-452. DOI ScienceOn
8	Freitag, D. G., R. T. Foster, R. T. Coutts, M. A. Pickard, and F. M. Pasutto. 1997. Stereoselective metabolism of rac-mexiletine by the fungus Cunninghamella echinulata yields the major mammalian metabolites hydroxymethylmexiletine and p-hydroxymexiletine. Drug Metab. Dispos. 25: 685-692.
9	Gessel, M., E. Hammer, M. Specht, W. Francke, and F. Schauer. 2001. Biotransformation of biphenyl by Paecilomyces lilacinus and characterization of ring cleavage products. Appl. Environ. Microbiol. 67: 1551-1557. DOI ScienceOn
10	Ferris, J. P., M. J. Fasco, F. L. Stylianopoulou, D. M. Jerina, J. W. Daly, and A. M. Jeffrey. 1973. Monooxygenase activity in Cunninghamella bainieri: Evidence for a fungal system similar to liver microsomes. Arch. Biochem. Biophys. 156: 97-103. DOI ScienceOn
11	Foster, G. R., R. T. Coutts, F. M. Pasutto, and A. Mozayani. 1988. Microbial metabolism of phenelzine and pheniprazine. Life Sci. 42: 285-292. DOI ScienceOn
12	Foster, G. R., D. L. Lister, J. Zamecnic, and R. T. Coutts. 1991. The biotransformation of tranylcypromine by Cunninghamella echinulata. Can. J. Microbiol. 37: 791-795. DOI ScienceOn
13	Camu, F., T. Beecher, D. P. Recker, and K. M. Verburg. 2002. Valdecoxib, a COX-2 specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am. J. Ther. 9: 43-51. DOI ScienceOn
14	Duhart, B. T., D. Zhang, J. Deck, J. P. Freeman, and C. E. Cerniglia. 1999. Biotransformation of protriptyline by filamentous fungi and yeasts. Xenobiotica 29: 733-746. DOI ScienceOn
15	Clark, A. M. and C. D. Hufford. 1991. Use of microorganisms for the study of drug metabolism - An update. Med. Res. Rev. 11: 473-501. DOI ScienceOn
16	Clark, A. M., J. D. McChesney, and C. D. Hufford. 1985. The use of microorganisms for the study of drug metabolism. Med. Res. Rev. 5: 231-253. DOI ScienceOn
17	Dodge, R. H., C. E. Cerniglia, and D. T. Gibson. 1979. Fungal metabolism of biphenyl. Biochem. J. 178: 223-230.
18	Zhang, D., H. Zhang, N. Aranibar, R. Hanson, Y. Huang, P. T. Cheng, et al. 2006. Structural elucidation of human oxidative metabolites of muraglitazar: Use of microbial bioreactors in the biosynthesis of metabolite standards. Drug Metab. Dispos. 34: 267-280.
19	Abel, A. M., A. J. Carnell, J. A. Davis, and M. Paylor. 2003. The synthesis of buprenorphine intermediates by regioselective microbial N- and O-demethylation reactions using Cunninghamella echinulata NRRL 1384. Enzyme Microb. Technol. 33: 743-748. DOI ScienceOn
20	Abourashed, E. A., A. M. Clark, and C. D. Hufford. 1999. Microbial models of mammalian metabolism of xenobiotics: An updated review. Curr. Med. Chem. 6: 359-374.
21	Zhang, J. Y., J. J. Yuan, Y. Wang, R. H. Bible Jr., and A. P. Breau. 2003. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Drug Metab. Dispos. 31: 491-501. DOI ScienceOn
22	Wong, Y. W. J. and P. J. Davis. 1989. Microbial models of mammalian metabolism: Stereoselective metabolism of warfarin in the fungus Cunninghamella elegans. Pharm. Res. 6: 982-985. DOI ScienceOn
23	Schwartz, H., A. Liebig-Weber, H. Hochstatter, and H. Bottcher. 1996. Microbial oxidation of ebastine. Appl. Microbiol. Biotechnol. 44: 731-735. DOI ScienceOn
24	Yuan, J. J., D. Yang, J. Y. Zhang, R. Bible Jr., A. Karim, and J. W. A. Findlay. 2002. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 30: 1013-1021. DOI ScienceOn
25	Vigne, B., A. Archelas, and R. Furstoss. 1991. Microbial transformations 18. Regiospecific para-hydroxylation of aromatic carbamate mediated by the fungus Beauveria sulfurescens. Tetrahedron 47: 1447-1458. DOI ScienceOn
26	Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, et al. 2000. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43: 1661-1663. DOI ScienceOn
27	Venisetty, R. K., S. Keshetty, and V. Ciddi. 2004. Optimization of surfactants and polymers to alter the morphology of matt forming fungal cultures, an improved way for fungal drug metabolism studies, Abstr. PB-P005, p. 282. Abstr. 64th FIP Congress, International Pharmaceutical Federation, New Orleans, U.S.A.
28	Talley, J. J., D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, et al. 2000. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 43: 775-777. DOI ScienceOn
29	Smith, R. V., P. J. Davis, A. M. Clark, and S. Glover-Milton. 1980. Hydroxylation of biphenyl by fungi. J. Appl. Bacteriol. 49: 65-73. DOI
30	Talley, J. J. 2000. Discovery of the second generation COX-2 inhibitor valdecoxib, p. 1. Abstr. 35th Midwest Regional Meeting of the American Chemical Society, St. Louis, Missouri.